Medicover reports Q2 results tomorrow. In our previous note, we expected a U-shaped recovery for Medicover's revenues, where patients return "slowly" to the clinics. We are more optimistic now with the general macro outlook and with Medicover's performance for 2020. We maintain our view of the company as resilient and well-managed, and a defensive investment.